NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.17. View Intra-Cellular Therapies' Earnings History.

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intra-Cellular Therapies.

8 Wall Street analysts have issued 1-year target prices for Intra-Cellular Therapies' stock. Their forecasts range from $16.00 to $73.00. On average, they expect Intra-Cellular Therapies' share price to reach $36.57 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.

News stories about ITCI stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Intra-Cellular Therapies earned a news impact score of -3.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the next few days. View News Stories for Intra-Cellular Therapies.

Intra-Cellular Therapies saw a drop in short interest in January. As of January 15th, there was short interest totalling 8,370,000 shares, a drop of 34.9% from the December 31st total of 12,850,000 shares. Based on an average daily trading volume, of 2,680,000 shares, the short-interest ratio is currently 3.1 days. Currently, 17.9% of the company's shares are short sold. View Intra-Cellular Therapies' Current Options Chain.

Some companies that are related to Intra-Cellular Therapies include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), United Therapeutics (UTHR), Evotec (EVTCY), Nektar Therapeutics (NKTR), FibroGen (FGEN), Mirati Therapeutics (MRTX), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), Blueprint Medicines (BPMC), Zai Lab (ZLAB) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Sarepta Therapeutics (SRPT), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC- (GWPH), Zynerba Pharmaceuticals (ZYNE) and Myovant Sciences (MYOV).

Intra-Cellular Therapies' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (1.61%), Rhenman & Partners Asset Management AB (0.90%), First Midwest Bank Trust Division (0.18%), California Public Employees Retirement System (0.16%), Assenagon Asset Management S.A. (0.03%) and Gainplan LLC (0.02%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Candriam Luxembourg S.C.A.. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Lawrence J Hineline, Mark Neumann, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

ITCI stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Assenagon Asset Management S.A., California Public Employees Retirement System, Gainplan LLC, SG Americas Securities LLC, Janney Montgomery Scott LLC and Kistler Tiffany Companies LLC. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $23.57.

Intra-Cellular Therapies has a market capitalization of $1.31 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.View Additional Information About Intra-Cellular Therapies.

The official website for Intra-Cellular Therapies is http://www.intracellulartherapies.com/.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]